1. STAT6 and phosphorylated STAT6 are differentially expressed in lymphomas.
- Author
-
Karpathiou G, Ferrand E, Papoudou-Bai A, Camy F, Honeyman F, Dumollard JM, and Peoc'h M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Immunohistochemistry, Lymphoma chemistry, Male, Middle Aged, Phosphorylation, STAT6 Transcription Factor analysis, Young Adult, Lymphoma metabolism, STAT6 Transcription Factor biosynthesis, STAT6 Transcription Factor metabolism
- Abstract
Background: The STAT6 pathway is implicated in the pathogenesis of various lymphomas; however, its immunohistochemical expression has not been fully investigated. Thus, the aim of this study was to investigate the immunohistochemical expression of the two forms of STAT6, phosphorylated or not, in a series of systemic lymphomas., Materials and Methods: Immunohistochemical expression of two antibodies, STAT6 (clone YE361) and pSTAT6 (clone Y641), which recognise the phosphorylated form of the molecule was studied in 60 lymphomas., Results: STAT6
YE361 expression was cytoplasmic, with 23.3% of the cases showing high expression. pSTAT6Y641 expression was mostly nuclear and found in 45% of the cases. pSTAT6Y641 nuclear expression was associated with the lymphoma type (p < 0.0001), as it was seen mostly in follicular, Hodgkin and angioimmunoblastic T cell lymphomas. STAT6YE361 cytoplasmic expression was also associated with lymphoma type (p = 0.001), as it was mostly found in diffuse large B cell and marginal B cell lymphomas. No association with PD-L1 expression, other clinicopathological data or prognosis was found., Conclusion: The two STAT6 clones are differentially expressed between lymphoma types., (Copyright © 2021 Elsevier GmbH. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF